Broadwood Capital Inc reported 5 positions worth $1.77B for the quarter ended Jun 30, 2026, up 36.1% on the prior quarter. It opened 0 new positions, added to 1, trimmed 0 and exited 0. Its largest holding is Monster Beverage Corp at 44% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| IMDX Insight Molecular Diagnostics Inc. | +753.0K | +6.3% | $4.44M | 4.23% |
No positions were reduced this quarter.
No new positions this quarter.
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | MNST Monster Beverage Corp | Consumer Staples | 16.22M | $779.32M | 44.02% | 0 | 0.0% | Unchanged | 0.83% |
| 2 | STAA Staar Surgical Co | Healthcare | 16.12M | $462.59M | 26.13% | 0 | 0.0% | Unchanged | 32.31% |
| 3 | AXON Axon Enterprise, Inc. | Technology | 693.5K | $388.79M | 21.96% | 0 | 0.0% | Unchanged | 0.85% |
| 4 | IMDX Insight Molecular Diagnostics Inc. | Healthcare | 12.68M | $74.84M | 4.23% | +753.0K | +6.3% | Added | 34.52% |
| 5 | LCTX Lineage Cell Therapeutics, Inc. | Healthcare | 49.56M | $64.92M | 3.67% | 0 | 0.0% | Unchanged | 19.6% |
Tip. Select a row to see that position’s full history at Broadwood Capital.
As of its Q2 2026 13F filing, Broadwood Capital Inc’s five largest positions were Monster Beverage Corp (MNST) at 44.0%, Staar Surgical Co (STAA) at 26.1%, Axon Enterprise, Inc. (AXON) at 22.0%, Insight Molecular Diagnostics Inc. (IMDX) at 4.2%, Lineage Cell Therapeutics, Inc. (LCTX) at 3.7% of the reported portfolio.
Broadwood Capital Inc reported a 13F portfolio worth $1.77B across 5 positions for Q2 2026. That is up 36.1% from the previous quarter.
Its largest purchases by value were Insight Molecular Diagnostics Inc. ($4.44M). It opened 0 new positions.
From the Form 13F-HR reports Broadwood Capital Inc files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.